Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2018 | Venetoclax combination therapy in relapsed ALL

There is an unmet need for treatment options for acute lymphoblastic leukemia (ALL) patients who have relapsed on multiple prior therapies. Thomas Alexander, MD, PhD, of the University of North Carolina School of Medicine, Chapel Hill, NC, presented data from his trial (NCT03181126) exploring the efficacy of the BCL2 inhibitors venetoclax and navitoclax with chemotherapy in these patient groups at the 23rd Congress of the European Hematology Association (EHA) 2018, in Stockholm, Sweden. In this video, he discusses certain ALL subgroups which respond better to BCL2 inhibition, how to extrapolate pediatric safety data from adult data, and the rationale behind developing combination therapies like this one when immunotherapy is coming to the forefront of ALL research and treatment.